There are currently 9 active clinical trials seeking participants for Melanoma (Skin) research studies. The states with the highest number of trials for Melanoma (Skin) participants are Ohio, Illinois, Minnesota and Michigan.
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
NCT05704647
Recruiting
To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug combination will also be studied.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Melanoma (Skin)
Register for Updates
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
NCT03543969
Recruiting
This pilot early phase I trial studies how well encorafenib, binimetinib, and nivolumab work in treating patients with BRAF mutant stage IIIC-IV melanoma. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with nivolumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving encorafenib, binimetinib, and nivolumab may kill more tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
Register for Updates
Rural Adult and Youth Sun Protection Study
NCT06439979
Recruiting
The purpose of this study is to help prevent skin cancer by improving the use of sun protective behaviors among youths living in rural communities in Utah and West Virginia.
Gender:
All
Ages:
Between 3 years and 7 years
Trial Updated:
05/29/2024
Locations: University of Utah, Salt Lake City, Utah +1 locations
Conditions: Melanoma (Skin), Skin Cancer
Register for Updates
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
NCT05786924
Recruiting
BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability, maximum tolerated dose (MTD) and the preliminary recommended Phase 2 dose (RP2D), and antitumor activity of BDTX-4933. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS non-G12C mutations or BRAF mutations, advanced/metastatic melanom... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/19/2024
Locations: Banner Health- MD Anderson Cancer Center, Gilbert, Arizona +9 locations
Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C
Register for Updates
Mentored Community Gardening for Individuals With Skin Cancer
NCT05648604
Recruiting
The investigators will conduct a single-arm pilot feasibility trial of mentored community gardening for melanoma survivors integrating dosimeters and accelerometers. Harvest for Health Together Arizona (H4H2-AZ) is an evidence-based program adapted for arid desert gardening that also addresses sun safety through group workshops and peer education. The primary aim is to evaluate adherence to the intervention.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Melanoma, Cancer Survivorship, Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma (Skin)
Register for Updates
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
NCT06400550
Recruiting
The goal of this study is to observe metabolic features associated with human melanoma tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Melanoma (Skin)
Register for Updates
MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma
NCT05655312
Recruiting
In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated in patients with unresectable and metastatic melanoma.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2024
Locations: University of Iowa, Iowa City, Iowa +7 locations
Conditions: Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma, Uveal, Mucosal Melanoma, Melanoma Stage III
Register for Updates
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
NCT05578872
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +24 locations
Conditions: Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
Register for Updates
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: University of Birmingham Alabama, Birmingham, Alabama +52 locations
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates